share_log

Barclays Maintains Underweight on Zimmer Biomet Holdings, Lowers Price Target to $125

Benzinga ·  May 31 14:16

Barclays analyst Matt Miksic maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Underweight and lowers the price target from $130 to $125.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment